Merck's Q3 2016 earnings call highlights strong performance, particularly with KEYTRUDA.  Significant FDA approvals and expanding clinical trial data for lung cancer, along with continued positive trends in other segments, suggest a positive outlook for the near future.  Management's optimistic tone and upward revisions to revenue and EPS guidance should positively impact the stock price.
[2]
